Technology | Mammography | December 07, 2018

FDA Clears iCAD's ProFound AI for Digital Breast Tomosynthesis

Artificial intelligence-based technology improves cancer detection rates 8 percent on average, decreases unnecessary patient recalls 7 percent

FDA Clears iCAD's ProFound AI for Digital Breast Tomosynthesis

December 7, 2018 — iCAD Inc. announced clearance by the U.S. Food and Drug Administration (FDA) for their latest, deep-learning, cancer detection software solution for digital breast tomosynthesis (DBT), ProFound AI. The solution built on artificial intelligence (AI) is now available to healthcare facilities in the U.S.

The FDA clearance is based on positive clinical results from a large reader study completed earlier this year and presented at the 2018 Radiological Society of North America (RSNA) annual meeting, Nov. 25-30 in Chicago. The research was performed with 24 radiologists who read 260 tomosynthesis cases both with and without iCAD’s ProFound AI solution. The findings show increased cancer detection rates, reduced false positive rates and patient recalls, and a significant decrease in interpretation times.

“This technology shows tremendous promise in assisting radiologists in detecting cancers, reducing recalls and increasing efficiency when reading tomosynthesis studies,” said Emily Conant, M.D., professor and chief, Division of Breast Imaging, vice chair of faculty development, Department of Radiology at the Hospital of the University of Pennsylvania. “Clinical data shows that when tomosynthesis readers use the ProFound AI algorithm, case-level sensitivity is improved by 8 percent on average and reading times are significantly decreased. Radiologists with various levels of expertise may benefit from this AI-driven technology when reading large tomosynthesis data sets.”

ProFound AI is a high-performance, deep-learning, cancer detection and workflow solution for DBT, delivering improvement of cancer detection rates by an average of 8 percent and decreasing unnecessary patient recall rates by an average of 7 percent. The new technology is trained to detect malignant soft-tissue densities and calcifications. It also provides radiologists with scoring information representing the likelihood that a detection or case is malignant based on the large dataset of clinical images used to train the algorithm.

In addition to improving clinical performance related to breast cancer detection and false positive rates, study results showed ProFound AI can reduce radiologists’ reading time by more than 50 percent on average. An increase in reading time has been a significant challenge for radiologists when moving from 2-D to 3-D mammography.

The solution is currently available for use with - DBT systems in the U.S., Canada and Europe.

For more information: www.icadmed.com

Related Content

Philips Earns FDA Clearance for DigitalDiagnost C90 DR System
Technology | Digital Radiography (DR) | February 20, 2019
Philips announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the...
Congress Directs FDA to Establish Federal Breast Density Inform Standard
News | Breast Density | February 19, 2019 | Jeff Zagoudis, Associate Editor
As part of a federal spending bill passed late Friday, Congress directed the U.S. Food and Drug Administration (FDA) to...
Philips Launches Zenition Mobile C-arm Platform
Technology | Mobile C-Arms | February 18, 2019
Philips announced the launch of Philips Zenition, its new mobile C-arm imaging platform. Mobile C-arms are X-ray...
Amazon Comprehend Medical Brings Medical Language Processing to Healthcare
News | Artificial Intelligence | February 15, 2019
Amazon recently announced Amazon Comprehend Medical, a new HIPAA-eligible machine learning service that allows...
Fujifilm Exhibits Enterprise Imaging Solutions and Artificial Intelligence Initiative at HIMSS 2019
News | Enterprise Imaging | February 15, 2019
Fujifilm Medical Systems U.S.A. Inc. and Fujifilm SonoSite Inc. showcased their enterprise imaging and informatics...
IBM Watson Health Announces New AI Collaborations With Leading Medical Centers
News | Artificial Intelligence | February 14, 2019
IBM Watson Health announced plans to make a 10-year, $50 million investment in research collaborations with two...
Medivis Launches SurgicalAR Augmented Reality Platform
Technology | Advanced Visualization | February 14, 2019
Medical imaging and visualization company Medivis officially unveiled SurgicalAR, its augmented reality (AR) technology...
Densitas Enters Partnership Agreement With TeleMammography Specialists
News | Breast Density | February 14, 2019
Breast imaging analytics company Densitas Inc. announced a new collaboration partnership with TeleMammography...
Office of the National Coordinator Releases Proposed Rule on Healthcare Data Interoperability
News | Information Technology | February 14, 2019
The U.S. Department of Health and Human Services (HHS) has proposed a new rule to support seamless and secure access,...
Sponsored Content | Webinar | Artificial Intelligence | February 14, 2019
This Nuance-sponsored ITN webinar will be held at 1 p.m. Eastern time, Tuesday, Feb. 26, 2019.